Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Application
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
C18 Ceramide-d3 (d18:1/18:0) is intended for use as an internal standard for the quantification of C18 Ceramide (d18:1/18:0) (Item No. 19556) by GC- or LC-MS. C18 Ceramide is an endogenous bioactive sphingolipid. It is the primary short-chain ceramide found in brain tissue whose synthesis is regulated by longevity-assurance homologue 1 (Lass1) in mice.1 Increased expression of C18 ceramide reduces cell growth in UM-SCC-22A squamous cell carcinoma cells.2 It is selectively downregulated in 32 human head and neck squamous cell carcinoma tumor tissues as compared to non-squamous tumor tissues. C18 Ceramide concentration is significantly higher in muscle tissue of type 2 diabetic patients compared with non-diabetic patients and is positively correlated to body mass index and inversely related to insulin sensitivity.3 [Matreya, LLC. Catalog No. 2201]
WARNING This product is not for human or veterinary use.
1. Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. Biochem J. 390(Pt. 1), 263-271 (2005).
2. Defects in cell growth regulation by C18:0-
3. Muscle sphingolipids during rest and exercise: A C18:0 signature for insulin resistance in humans. Diabetologia 59(3), 785-791 (2016).
Multi-